Injectable Drug Recall Issued Nationwide After Glass and Paraformaldehyde Found in Papaverine Injection

A nationwide injectable drug recall has been announced after visible particulate contamination was discovered in a prescription medication distributed across the United States. The affected product, Papaverine Hydrochloride Injection, USP, 60 mg/2 mL, is being recalled after the manufacturer identified particles of glass and paraformaldehyde in a specific production lot.

The recall has raised concerns because contaminated injectable medications can pose serious health risks. According to the recall notice, if foreign particles enter the bloodstream, they may block blood vessels and potentially lead to life threatening complications such as stroke, pulmonary embolism, heart damage, or even death.

Nationwide Injectable Drug Recall Announced

American Regent Inc. voluntarily announced the recall on July 24, 2026, after detecting visible particulate matter in one lot of Papaverine Hydrochloride Injection. The U.S. Food and Drug Administration (FDA) published the recall notice on July 27, 2026, informing healthcare providers, distributors, and consumers about the potential risks associated with the affected medication.

The recalled product had been distributed nationwide beginning on September 30, 2025, making it available to healthcare facilities across the country.

Although no injuries or adverse health events had been reported at the time of the announcement, the manufacturer decided to recall the product as a precautionary measure to protect patient safety.

Why the Recall Matters

Injectable medications are delivered directly into the body, bypassing many of the natural filtering systems that protect against contaminants. As a result, any foreign particles present in an injection can create serious medical complications.

According to the recall notice, visible glass or paraformaldehyde particles may cause:

• Local irritation at the injection site
• Pain and swelling
• Inflammation
• Damage to surrounding tissue
• Blockage of blood vessels
• Stroke
• Heart complications
• Lung complications
• Death in severe cases

Patients with existing cardiovascular disease or pulmonary disorders may face an even greater risk if contaminated particles travel through the bloodstream.

What Is Papaverine Hydrochloride?

Papaverine Hydrochloride is a prescription medication classified as a smooth muscle relaxant and vasodilator. It works by relaxing muscles within blood vessel walls, allowing improved blood flow throughout the body.

Healthcare providers prescribe Papaverine Hydrochloride for several medical conditions, including:

• Visceral muscle spasms
• Certain circulation disorders
• Poor blood flow
• Erectile dysfunction in specific clinical situations

The medication is supplied as a sterile injectable solution in single dose vials and is typically administered under medical supervision.

What Is Paraformaldehyde?

Paraformaldehyde is a solid polymer derived from formaldehyde and is commonly used in laboratories, manufacturing facilities, and industrial applications.

It is not intended to be present in injectable medications. Its presence inside a sterile pharmaceutical product indicates contamination and raises concerns regarding manufacturing quality and patient safety.

The recall notice does not explain how either the glass particles or paraformaldehyde entered the affected production lot.

Details of the Recalled Product

The recall applies only to one specific lot of Papaverine Hydrochloride Injection.

Product information includes:

• Product: Papaverine Hydrochloride Injection, USP
• Strength: 60 mg/2 mL
• Package: Single dose vial
• Lot Number: 25202
• NDC: 0517-4002-25
• Expiration Date: November 30, 2026

No other lots were included in the recall announcement.

What Patients Should Do

Patients who believe they may have received the recalled medication should avoid using it until speaking with their physician or healthcare provider.

Medical professionals recommend that patients seek immediate medical attention if they experience symptoms such as sudden chest pain, difficulty breathing, weakness on one side of the body, severe swelling, or other unusual reactions following an injection.

Individuals should never continue using a recalled injectable medication without guidance from a qualified healthcare professional.

Guidance for Healthcare Providers

American Regent has instructed distributors, wholesalers, hospitals, pharmacies, and healthcare facilities to immediately stop using the affected lot.

Facilities should:

• Remove the recalled product from inventory.
• Return the affected lot to the place of purchase or dispose of it according to recall instructions.
• Notify appropriate clinical staff.
• Follow replacement procedures provided by the manufacturer.

The company stated that customers are being contacted directly through official recall letters.

No Reported Injuries So Far

One reassuring aspect of this injectable drug recall is that, at the time of the announcement, American Regent reported that it had not received any confirmed reports of adverse events linked to the recalled lot.

Nevertheless, recalls involving injectable medications are treated with a high level of urgency because contamination can lead to severe complications even if only a small number of patients are affected.

Reporting Side Effects

Patients and healthcare providers who believe they have experienced adverse reactions related to the recalled medication are encouraged to report them through the FDA's MedWatch Adverse Event Reporting Program. Reports can also be submitted directly to American Regent as part of the company's product quality monitoring process.

Timely reporting helps health authorities investigate potential safety issues and determine whether additional regulatory actions are necessary.

Importance of Pharmaceutical Quality Control

Drug recalls such as this highlight the importance of strict manufacturing standards within the pharmaceutical industry. Injectable medications undergo rigorous quality testing because they enter the bloodstream directly. Even microscopic contaminants can create significant health risks.

Manufacturers routinely conduct inspections and quality assurance testing throughout production. If contamination is discovered after distribution, companies often issue voluntary recalls in coordination with the FDA to minimize potential harm to patients.

Healthcare providers also play an essential role by monitoring recalls, removing affected products from circulation, and informing patients when necessary.

Final Thoughts

This latest injectable drug recall serves as an important reminder that pharmaceutical safety remains a top priority for manufacturers and regulators alike. While no injuries have been linked to the recalled Papaverine Hydrochloride Injection lot, the presence of glass and paraformaldehyde particles prompted swift action to reduce potential risks.

Patients should not panic if they believe they may have received the recalled medication, but they should contact their healthcare provider for guidance. Healthcare facilities are expected to follow the recall instructions and ensure that the affected lot is no longer used.

As investigations continue, additional information may become available regarding the source of the contamination and any further regulatory actions.

Source

• American Regent Inc. voluntary recall announcement.
• U.S. Food and Drug Administration (FDA) recall notice.
• Mayo Clinic drug information on Papaverine Hydrochloride.

Disclaimer

This article is intended for informational and educational purposes only and should not be considered medical advice. If you have received the recalled medication or are experiencing symptoms after an injection, contact your physician or another qualified healthcare professional immediately. Always rely on official guidance from the manufacturer, the FDA, and your healthcare provider regarding recalled medications.